Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032524 · ClinicalTrials.gov registry record · Phase 2
Avalglucosidase Alfa Extension Study
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02032524 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 19 participants.
The verdict
NCT02032524, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Primary Objective: Long-term safety and pharmacokinetics (PK) of avalglucosidase alfa Secondary Objective: Long-term effect of avalglucosidase alfa on pharmacodynamic variables
Interventions
- DRUG Avalglucosidase Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-02-27 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032524
The ClinicalTrials.gov registry entry for NCT02032524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avalglucosidase Alfa is the first listed.
NCT02032524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032524 about?
NCT02032524 is a clinical study titled "Avalglucosidase Alfa Extension Study". Primary Objective: Long-term safety and pharmacokinetics (PK) of avalglucosidase alfa Secondary Objective: Long-term effect of avalglucosidase alfa on pharmacodynamic variables
What is the current status of trial NCT02032524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2014-02-27. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT02032524?
The interventions under investigation include: Avalglucosidase Alfa (DRUG).
Who is sponsoring clinical trial NCT02032524?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.